Research Article

Key stakeholders’ perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa

Published in: African Journal of AIDS Research
Volume 22 , issue 1 , 2023 , pages: 18–26

DOI: 10.2989/16085906.2023.2169177

Author(s): Ivana Beesham University of the Witwatersrand, South Africa , Cecilia Milford University of the Witwatersrand, South Africa , Dvora L Joseph Davey University of Cape Town, South Africa , Jenni Smit University of the Witwatersrand, South Africa , Leila E Mansoor University of KwaZulu-Natal, South Africa , Mags Beksinska University of the Witwatersrand, South Africa

Keywords: HIV prevention options , PrEP , post-trial access , standard of prevention

Download full text Get new issue alerts

Abstract

Introduction: HIV-prevention and endpoint-driven clinical trials enrol individuals at substantial risk of HIV. Recently, these trials have provided oral pre-exposure prophylaxis (PrEP) as HIV-prevention standard of care; however, data on PrEP uptake and use during the trial and post-trial access are lacking.

« Evaluating HIV policy: a gender analysis of the representation of women and men in UNAIDS HIV-prevention guidelines

Roles and responsibilities of expert clients in adolescent HIV service delivery in Eswatini: a conventional content analysis »